SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing heightened market activity following a high-profile White House quantum policy event and the launch of a new quantum-focused space initiative, driving active community debate over potential government-backed growth versus volatility. Traders are closely monitoring the stock's technical levels, upcoming technical webinars, and its pending inclusion in the Russell index, all of which are fueling speculation about a breakout.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending following the disappointing Phase 3 trial results for its cancer drug sigvotatug vedotin, alongside concerns regarding ongoing leadership transitions. The community remains deeply divided, with some expressing frustration over recent pipeline setbacks and management's strategic direction, while others continue to view the stock as a value-based, long-term dividend opportunity.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is attracting heavy attention as the broader quantum sector sees significant momentum fueled by government funding announcements, new executive orders, and anticipation surrounding upcoming IPOs in the industry. The community is actively debating the sustainability of this rally, with bulls highlighting the potential for long-term disruptive growth while skeptics point to insider selling and concerns regarding high valuations for companies still in early stages of commercialization.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently facing intense selling pressure as it hits new 52-week lows, with market sentiment heavily divided between those who view the decline as a valuation reset and others who see it as a bearish breakdown of its long-term technical structure. Community discussion is dominated by heated debates regarding institutional accumulation versus retail capitulation, fueled by reports of contract shifts in Europe and skepticism toward the stock's high valuation multiples compared to its growth trajectory.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is drawing significant investor interest as shareholders look for a potential turnaround driven by new leadership and international expansion efforts, despite ongoing concerns over short interest and competitive pressures. The community remains divided, with some betting on a buyout catalyst or short squeeze while others highlight operational frustrations and dividend sustainability.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. (QUBT) is surging alongside the broader quantum sector following a major government push for quantum innovation, which has renewed investor interest in hardware and infrastructure plays. The community is actively debating the potential for a short squeeze, citing high short interest and institutional interest as investors track which companies can successfully move from research phases to scalable, real-world commercial deployment.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is facing downward pressure amid broader hyperscaler concerns over AI infrastructure spending, with investors closely watching Prime Day as a gauge for consumer health. While the community is debating the stock's valuation versus its massive capital expenditure, many remain focused on the long-term potential of AWS and the company's aggressive push into custom AI silicon.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing heightened investor attention driven by strong momentum in the weight-loss peptide space and analyst upgrades that highlight its growth potential. The community is actively debating the company's long-term platform shift toward a broader healthcare ecosystem while keeping a close eye on the upcoming FDA advisory meeting as a potential fundamental catalyst.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending following a significant clinical milestone, with investors closely watching its progress in late-stage trials for psychiatric disorders. Community sentiment is currently polarized, featuring both optimistic retail investors anticipating upcoming clinical data and vocal skeptics who are raising concerns about long-term financial dilution.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

iShares Semiconductor ETF (SOXX) continues to see intense volatility and heavy retail participation as investors remain polarized over the sustainability of the ongoing AI infrastructure rally. While some market participants are aggressively buying dips, citing long-term conviction in chip demand, others express deep skepticism and are actively shorting the sector, bracing for potential reversals driven by macro-economic uncertainty and sector-wide overvaluation concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Altimmune Worth Buying Ahead of 2026 Catalysts?

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.

Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.

Madrigal Pharmaceuticals Q1 Earnings Call Highlights

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported first-quarter 2026 net sales of $311.3 million as executives said demand for its MASH therapy Rezdiffra continued to build in a market they described as still early in development. On the company's earnings call, management highlighted patient growth...

Madrigal Pharmaceuticals (NASDAQ:MDGL) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $620.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Wednesday...

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of +9.97% and +3.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Madrigal Pharmaceuticals Posts Wider Loss In Q1

(RTTNews) - Wednesday, Madrigal Pharmaceuticals, Inc. (MDGL) announced its first-quarter financial results, reporting a net loss of $94.4 million, or $3.25 a share, compared to $73.2 million, or $2.61 a share, in the previous year...

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowheads clinical stage RNA...

Vanguard Group Inc. Trims Stake in Madrigal Pharmaceuticals, Inc. $MDGL

Vanguard Group Inc. reduced its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 0.2% in the fourth quarter, according to its most recent 13F filing with the...

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$512.88
Prev Close	$505.75
Open	$513.23
Dividend Yield	0.00%
50-Day Moving Average	$509.57
Beta	0.84
Avg. Volume	299,691.18
PE Ratio	-40.07

52-Week High	$615.00
52-Week Low	$277.64
Market Capitalization	$11.66B
EPS (Annual)	-$12.85
Price to Book	21.75
Revenue Per Employee	$1.05M

Feed

News

Sentiment

Earnings

Fundamentals

Info

MDGLMadrigal Pharmaceuticals Inc

Latest MDGL News